Top View
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy Ayman Al‑Hendy, M.D., Ph.D., Andrea S
- A Women's Health Update
- Phase 3 HERO Study Design: Evaluation of the Safety and Efficacy of Relugolix, a Novel Oral Gnrh Receptor Antagonist, in Men with Advanced Prostate Cancer
- 214621Orig1s000
- Orgovyx (Relugolix) C21100-A
- Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
- Oral Gonadotropin-Releasing Hormone Antagonists NOTICE
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Endometriosis
- Abbvie's Orilissa, Myovant's Relugolix Both Expected to Face Similar Payer
- Drug Monograph
- LHRH Agonists and Antagonist
- Specialty Pharmacy Drug List Specialty Medications List
- Gonadotropin-Releasing Hormone Antagonists – Myfembree® (Relugolix, Estradiol, and Norethindrone Acetate Tablets)
- Endometriosis
- 25 November 2020 Gnrh Antagonist TAK-385 Announcement of Phase 3
- New 0Ral Gonadotropin-Releasing Hormone (Gnrh) Antagonist
- 10K Annual Report 2017
- Report on the Deliberation Results December 4, 2018 Pharmaceutical
- Ryeqo, INN: Relugolix / Estradiol / Norethisterone Acetate
- Relugolix, an Oral Gonadotropin-Releasing Hormone